Song et al clarified that the significantly up-regulated NCAPG confered trastuzumab resistance to HER2-positive breast cancer by activating the SRC/STAT3 signal axis, which illustrated that NCAPG also played a non-negligible role in tumor resistance. Here, ERBB2 is linked to breast cancer.